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A B S T R A C T
Objective: To assess the effects of non-invasive ventilation (NIV) in emergency department (ED) patients with
acute heart failure (AHF) on short term outcomes.
Methods: Patients from the EAHFE Registry (a multicenter, observational, multipurpose, cohort-designed data-
base including consecutive AHF patients in 41 Spanish EDs) were grouped based on NIV treatment (NIV+ and
NIV–groups). Using propensity score (PS) methodology, we identified two subgroups of patients matched by 38
covariates and compared regarding 30-day survival (primary outcome). Interaction was investigated for age, sex,
ischemic cardiomyopathy, chronic obstructive pulmonary disease, AHF precipitated by an acute coronary syn-
drome (ACS), AHF classified as hypertensive or acute pulmonary edema (APE), and systolic blood pressure
(SBP). Secondary outcomes were intensive care unit (ICU) admission; mechanical ventilation; in-hospital, 3-day
and 7-day mortality; and prolonged hospitalization (> 7 days).
Results: Of 11,152 patients from the EAHFE (age (SD): 80 (10) years; 55.5% women), 718 (6.4%) were NIV+
and had a higher 30-day mortality (HR=2.229; 95%CI= 1.861–2.670) (p < 0.001). PS matching provided 2
groups of 490 patients each with no significant differences in 30-day mortality (HR=1.239;
95%CI=0.905–1.696) (p= 0.182). Interaction analysis suggested a worse effect of NIV on elderly patients
(> 85 years, p < 0.001), AHF associated with ACS (p=0.045), and SBP < 100mmHg (p < 0.001). No sig-
nificant differences were found in the secondary endpoints except for more prolonged hospitalizations in NIV+
patients (OR=1.445; 95%CI= 1.122–1.862) (p=0.004).
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Conclusion: The use of NIV to treat AHF in ED is not associated with improved mortality outcomes and should be
cautious in old patients and those with ACS and hypotension.
1. Introduction
Non-invasive ventilation (NIV) for ventilatory support is commonly
used in several types of respiratory failure. Patients with acute heart
failure (AHF) may receive NIV, especially those presenting with acute
pulmonary edema (APE). A meta-analysis of 15 clinical trials published
between 1988 and 2005 concluded that NIV reduced the need for in-
tubation and mortality in patients with APE and that there were no
differences between the two common NIV modalities: continuous po-
sitive airway pressure (CPAP) and bi-level positive airway pressure
(BIPAP) [1]. However, most studies had a small number of patients and,
overall, only 389 patients were treated with NIV in these 15 studies. In
one large evaluation from the retrospective ADHERE heart failure da-
tabase reported in 2008, Tallman et al. compared the outcomes of 2430
patients with severe respiratory distress receiving NIV versus those with
immediate endotracheal intubation (ETI). Regardless of the ultimate
need for ETI, patients receiving NIV fared no worse than the cohort
receiving immediate ETI, suggesting that, compared to the alternative
of ETI, NIV may be a reasonable intervention in AHF patients pre-
senting with severe respiratory distress [2].
Nonetheless, recent studies have introduced doubt about the real
benefit of NIV in terms of improving short-term mortality. The 3 CPO
study by Gray et al. [3], one of the largest randomized controlled trials
(RCT) in this setting [4], reached conclusions different from those of the
aforementioned meta-analysis and generated a great deal of con-
troversy. These authors randomized 1069 patients with APE to receive
NIV or standard oxygen therapy and found that although NIV induced a
more rapid improvement in respiratory distress and metabolic dis-
turbance than standard oxygen therapy, it had no effect on 7-day
mortality. Finally, a more recent review has highlighted that, although
hospital mortality seems to be reduced by NIV, the evidence to date on
the potential benefit of NIV in reducing mortality is entirely derived
from small trials, and further large-scale trials are needed [5].
Unfortunately, some of the RCT data available on the outcomes of
AHF patients in whom NIV is used are from the well-controlled setting
of an intensive care unit (ICU) and are not well represented from the
less controlled emergency department (ED) environment. The chal-
lenges of interpreting non-ED data applied to the ED population may
increase the risk of misapplication. The reasons for this may be the
result of greater variation in the population, a higher likelihood of
misdiagnosis, a larger range in illness severity, and that NIV may be
started in the ED (and even by prehospital emergency medical systems
-EMS-) and are often removed in the ED itself due to the fact that NIV
can improve AHF patient's clinical status in a few hours [6–8]. More-
over, the inclusion and exclusion criteria that a RCT imposes on the
final sample of patients selected for analysis excludes a large portion of
patients, often surpassing 80% [8]. Therefore, although there is no
doubt that for patients able to tolerate NIV the improvement of symp-
toms is greater and faster, the effects of NIV on short-term mortality are
still controversial when it is used in the ED setting in real world con-
ditions. For this reason, the objective of the present study was to assess
the effects on short-term outcome of the use of NIV in the ED setting to
treat patients diagnosed with AHF.
2. Patients and methods
2.1. Study setting
The present study was carried out using the patients included in the
EAHFE (Epidemiology of Acute Heart Failure in Emergency
Department) Registry. This is a multicenter, observational, multi-
purpose, cohort-designed database that includes consecutive patients
diagnosed with AHF in 41 Spanish EDs (approximately 7% of EDs of the
Spanish Public Health Care System) including both university and
community hospitals from all areas of the country. The characteristics
of the EAHFE Registry have been published elsewhere [9–11]. For the
present study, we used Phases 3, 4, and 5 EAHFE Registry patients.
These phases were respectively carried out in 2011 (2months of re-
cruitment, 25 participating EDs, n= 3414), 2014 (2months, 27 EDs,
n=3233), and 2016 (2months, 30 EDs, n= 4715), with similar re-
cruitment dynamics along the 3 periods. Briefly, patients were included
by the attending emergency physicians, all of whom received specific
instructions regarding the study protocol during a meeting held in every
ED the week before each recruitment period. All cases were double-
checked by the principal investigator of each center prior to inclusion
into the database in order to ascertain that patients met the clinical
diagnostic criteria of AHF. In addition, when possible and available, the
diagnosis was confirmed by natriuretic peptide determination or
echocardiography, following the European Society of Cardiology cri-
teria [12], during ED or hospitalization stay (approximately 92% of
cases). Patients with clinical diagnostic criteria, but without echo-
cardiographic or natriuretic peptide determinations, were accepted in
order to have a cohort similar to that observed in the routine emergency
medicine practice. Final diagnostic adjudication was completed by the
principal investigator of each center. All principal investigators were
provided with a dictionary of terms to ensure common definitions
(available in Supplementary Table 1). The only exclusion criterion in
the EAHFE Registry was patients with a primary diagnosis of ST-ele-
vation myocardial infarction (STEMI) who concurrently developed AHF
(approximately 3% of AHF cases), as these patients follow a very dif-
ferent clinical pathway that frequently by-passes the ED.
2.2. Variables analyzed
We collected 38 variables potentially related to prognosis in every
patient included in the study. This included demographics, clinical
history, presentation, and treatments based on the authors' consensus
after review of previous literature [13–15]. These covariates were re-
ported in specific case report forms during ED attendance (see Sup-
plementary Table 1). Interventions, treatments and patient allocation
(hospital admission or discharge) were entirely based on the decisions
of the attending ED physician. Subsequent follow-up by telephone
contact and consultation of medical records was performed between
days 31 and 90 after ED attendance in order to detect all-cause death.
The whole EAHFE Registry protocol was approved by a single central
Ethical Committee at the Hospital Universitario Central de Asturias
(Oviedo, Spain), with reference numbers 49/2010, 69/2011, 166/13,
and 160/15. Due to the non-interventional design of the study, Spanish
legislation allows the remaining centers participating in a multicenter
study to include patients with central Ethical Committee approval
provided that their local Ethical Committees are duly informed about
their participation. All patients gave informed consent to be included in
the EAHFE Registry and to be contacted for follow-up. Around 2% of
patients fulfilling the inclusion and exclusion criteria refused to parti-
cipate and did not sign informed consent.
2.3. Statistical analysis
The classification variable was the use of NIV (NIV+ and NIV-
groups, respectively) in the ED. Thirty-eight covariates were evaluated
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by the chi-square or Student's t-test (or Mann-Whitney U test when
appropriate) depending on whether they were qualitative or quantita-
tive variables, respectively. We used propensity score (PS) matching
methodology to obtain two comparable cohorts in the NIV+ and NIV-
groups. A PS was estimated for each of the patients [16] using multi-
variate logistic regression and determined the probability that partici-
pants would receive NIV based on their individual characteristics
(covariates). For this purpose, we constructed a multivariable model
including the independent variables that significantly differed between
groups in the univariable analysis (defined as a p < 0.10) in order to
obtain pairs of patients with comparable epidemiological, baseline,
clinical and therapeutic characteristics. It has been demonstrated that
this method provides accurate estimates of the effect of a drug in ob-
servational settings by minimizing confounding factors by indication
[17], and it has been proposed as a solution to overcome immortal time
bias (from the patient's entrance into the cohort to study drug intake) in
pharmacologic and epidemiologic studies [18]. Finally, patients were
paired (1:1) according to the nearest neighbour approach within a
calliper width of 0.01. To assess the balance of covariates between
groups after PS matching,< 10% of relative difference of means or
proportions was considered to support the assumption of balance be-
tween the NIV+ and NIV- groups.
The primary endpoint was 30-day all-cause mortality, which was
determined by survival tables using the Kaplan-Meier method, and the
log-rank test was used for comparison between the NIV+ and NIV-
groups. The risk of all-cause death was calculated by estimation of
hazard ratios (HR) with the 95% confidence interval (95% CI) for pa-
tients of the NIV+ group compared to those of the NIV- group using the
Cox regression model, and was initially calculated for the entire cohort
(unadjusted) and then for the PS-matched groups. The subgroups of NIV
+ patients according to the modality of NIV used (CPAP or BIPAP)
were also analyzed. We also planned a priori to investigate interaction
for the primary endpoint (30-day mortality) in the PS-matched patients
for the following groups: elderly patients (cut-off: 85 years), sex, is-
chemic cardiomyopathy or chronic obstructive pulmonary disease
(COPD) as comorbidities, AHF precipitated by an acute coronary syn-
drome (ACS), AHF classified as hypertensive or APE forms, and low
systolic blood pressure (SBP) (cut-off: 100mmHg) using Cox models.
The secondary endpoints analyzed in the PS-matched patients were
need for ICU admission, need for OTI and mechanical ventilation, 3-
day, 7-day and in-hospital mortality, and prolonged hospitalization
(defined as> 7 days from ED admission to final hospital discharge). All
secondary endpoints were expressed by odds ratios (OR) and 95%CI for
the patients of the NIV+ group compared to the NIV- group. All sta-
tistical tests were performed with a two-sided type I error of 5%, and we
used statistical software (SPSS v 19.0) for all the calculations.
3. Results
Of the 11,380 patients consecutively included recruitment phases 3,
4 and 5 of the EAHFE Registry, 11,152 were included in the NIV-AHF
Study (Fig. 1). The mean age was 80 (10) years, and 55.5% were
women. This cohort had a high number of concomitant comorbidities,
and most presented some degree of limitation at baseline: 75.6% were
in NYHA class II or higher, and 58.3% had at least moderate depen-
dence (Barthel index of 90 or less points). The remaining clinical data
are shown in Table 1.
NIV was used in the ED in 718 patients (6.4%); CPAP in 317
(44,2%), BiPAP in 380 (52.9%), and both were attempted in 21 (2.9%).
NIV+ patients differed from NIV- in 22 of the 36 variables analyzed
(Table 1): they were younger; more frequently had hypertension, dia-
betes mellitus, chronic kidney disease, cerebrovascular disease, per-
ipheral vascular disease and COPD, and less frequently atrial fibrilla-
tion; had worse functional status at baseline (assessed by the Barthel
index); were more frequently receiving chronic treatment with nitrates
and amiodarone, and less frequently with digoxin; had a higher SBP and
heart rate, and lower pulse oximetry at ED arrival; has higher glycemia
and creatinine values during the acute decompensation; were more
frequently treated with intravenous diuretics, nitrates, morphine, in-
otropics/vasopressors at ED; and were more frequently hospitalized.
With respect to the primary endpoint of 30-day all-cause mortality,
1081 patients (9.7%) died during the 30-day follow up: 135 (18.8%) in
the NIV+ versus 946 (9.1%) in the NIV- group. The HR for the NIV+
group in the unadjusted analysis was 2.229 (95% CI: 1.861–2.670;
p < 0.001); with very similar curves and HRs when CPAP and BiPAP
modalities were analyzed separately (Fig. 2).
Propensity score matching for the 22 variables with significant
differences between groups provided 490 pairs of patients matched by
the probability of being treated with NIV. The median PSs for the NIV+
and NIV- patients were 0.160 (p25–75: 0.055–0.404) and 0.161
(P25–75: 0.005–0.404) (p= .998), respectively. These groups did not
significantly differ in any of the 36 independent variables, and in only
three variables (previous history of ischemic cardiomyopathy, and
treatment with an aldosterone-receptor blocker or amiodarone) did the
relative difference between both groups exceed 10% (Table 1).
After PS matching, there was no difference in the primary endpoint
between PS-matched groups, and the HR for NIV+ was HR=1.239
(95% CI: 0.905–1.696; p=0.182), with very similar results for CPAP
and BiPAP (Fig. 3). The pre-planned stratified analysis showed an in-
teraction with elderly age (> 85 years), AHF associated with ACS, and
with a low SBP (< 100mmHg), in all cases having poorer prognosis if
NIV was used versus if it was not used (Fig. 4).
The analysis of the secondary endpoints did not uncover significant
differences in terms of the need for intensive care admission after ED
management, need for ETI and mechanical ventilation, and 3-day, 7-
day or in-hospital mortality. However, patients in the NIV+ group
more frequently required prolonged hospitalization (OR: 1.445; CI
95%: 1.122–1.862; p= 0.004) (Table 2).
4. Discussion
The present study investigated the impact of ED use of NIV to treat
AHF patients in real world conditions and its association with short-
term patient outcomes. Except in very eldery subjects, hypotensive
11,380 patients diagnosed with AHF 
(coming from the EAHFE 3, 4 and 5 Registries)
11,283 patients diagnosed with AHF for
whom use of NIV was recorded
11,152 patients diagnosed with AHF for
whom use of NIV was recorded and 
outcome is known
718 patients (6.4%) 
received NIV in the ED
NIV Group
10,434 patients (93.6%)
did not receive NIV in the ED
Not NIV Group (Controls)
490 patients
NIV Group
490 patients
Not NIV Group (Controls)
Propensity score
(matched by 22 discordant variables)
77 patients use of NIV not recorded
131 patients lost at follow up
Fig. 1. Flow chart of the patients studied.
NIV: non-invasive ventilation; COPD: chronic obstructive pulmonary disease; ED: emer-
gency department.
Ò. Miró et al. European Journal of Internal Medicine xxx (xxxx) xxx–xxx
3
patients, and AHF associated with ACS, our results suggest that NIV
does not change 30-day all-cause mortality, although NIV may be as-
sociated with longer hospitalization. In view of our results which con-
tradict those described in most RCT but are in line with those of the
3CPO trial, we believe that the use of NIV in the ED by emergency
physicians to treat patients with AHF should be aimed at the ameli-
oration of symptoms rather than to improvement of short-term survival.
Two main reasons could explain our results, which may be some-
what unexpected since NIV is widely used to treat AHF patients in the
emergency arena. The first reason is that there is no a clear consensus in
heart failure guidelines about when and in whom NIV should be ap-
plied. The NICE guidelines recommend to not routinely use NIV in
people with AHF and cardiogenic APE, although it should to be con-
sidered for patients with respiratory distress [4]. This is different from
the European Society of Cardiology (ESC) guidelines, which state that
NIV should be considered in patients with respiratory distress (re-
spiratory rate > 25 breaths/min, SpO2 < 90%) and started as soon as
possible in order to decrease respiratory distress and reduce the rate of
mechanical endotracheal intubation (class IIa recommedation, level of
evidence B). Nonetheless, the ESC guidelines warn about NIV use in
Table 1
Characteristics of patients included in the NIV-AHF Study and comparison between the two treatment groups.
Groups coming from the whole cohort Propensity-score matched groups
Total Missing
values
NIV+ NIV- p value NIV+ NIV- p value RDa (%)
N=11,152 (n
[%])
(n[%]) N=718 (n
[%])
N=10,434 (n
[%])
N=490 (n
[%])
N=490 (n
[%])
Demographic data
Age (years) (mean (SD)) 80 (10) 16 (0.1) 79 (9) 80 (10) < 0.001 79 (10) 79 (11) 0.510 0
Female 6167 (55.5) 44 (0.4) 392 (54.7) 5575 (55.6) 0.697 268 (54.8) 273 (55.8) 0.797 −1.8
Comorbidities
Hypertension 9361 (84) 11 (0.1) 626 (87.2) 8735 (83.8) 0.019 425 (86.7) 428 (87.3) 0.849 −0.6
Diabetes mellitus 4678 (42) 12 (0.1) 389 (54.2) 4289 (41.2) < 0.001 258 (52.7) 273 (55.7) 0.369 −5.4
Dyslipidemia 4959 (44.5) 12 (0.1) 336 (46.8) 4623 (44.4) 0.218 234 (47.8) 241 (49.2) 0.701 −2.8
Ischemic heart disease 3210 (28.8) 11 (0.1) 216 (30.1) 2994 (28.7) 0.462 136 (27.8) 164 (33.5) 0.061 −13.0
Chronic kidney failure 2978 (26.7) 10 (0.1) 225 (31.4) 2753 (26.4) 0.004 165 (33.7) 165 (33.7) 1.000 0
Cerebrovascular disease 1468 (13.2) 12 (0.1) 118 (16.4) 1350 (13) 0.009 75 (15.3) 72 (14.7) 0.858 +4.1
Atrial fibrillation 5516 (49.5) 9 (0.1) 279 (38.9) 5237 (50.2) < 0.001 207 (42.2) 204 (41.6) 0.897 +1.4
Peripheral arterial disease 1045 (9.4) 13 (0.1) 92 (12.8) 953 (9.1) 0.001 57 (11.6) 59 (12.0) 0.921 −3.3
Heart valve disease 2989 (26.8) 11 (0.1) 181 (25.2) 2808 (26.9) 0.332 124 (25.3) 120 (24.5) 0.825 +3.3
COPD 2682 (24.1) 12 (0.1) 226 (31.5) 2456 (23.6) < 0.001 160 (32.7) 159 (32.4) 1.000 +0.9
Dementia 1430 (12.8) 11 (0.1) 105 (14.6) 1325 (12.7) 0.150 67 (13.7) 67 (13.7) 1.000 0
Prior episode of heart failure 6396 (57.8) 90 (0.8) 431 (60.1) 5965 (57.7) 0.213 299 (61.0) 284 (58.0) 0.362 +5.2
Baseline status
Barthel Index (points) (mean
(SD))
79 (24) 1360 (12.2) 74 (25) 79 (24) < 0.001 73 (26) 75 (28) 0.436 −2.7
NYHA class II or higher 8411 (75.6) 690 (6.2) 551 (80.7) 7360 (75.3) < 0.001 388 (80.3) 372 (78.3) 0.327 +2.6
LVEF (%) (mean (SD)) 51 (15) 4995 (44.8) 51 (16) 51 (15) 0.815 51 (16.3) 49 (15.6) 0.088 +4.1
Chronic treatments
Diuretics 8095 (74.6) 306 (2.7) 525 (74.5) 7570 (74.6) 0.951 363 (71.1) 349 (71.2) 0.325 −0.1
ACE inhibitor or ARB 6346 (57.1) 31 (0.3) 415 (58) 5931 (57) 0.644 281 (57.3) 302 (61.6) 0.193 −7.0
Beta-blocker 4613 (42.5) 309 (2.8) 280 (39.8) 4333 (42.7) 0.134 198 (38.6) 209 (42.7) 0.217 −9.4
Aldosterone-receptor blocker 1812 (16.7) 305 (2.7) 126 (17.9) 1686 (16.6) 0.420 84 (17.1) 70 (14.3) 0.254 +19.6
Nitrates 1857 (17.1) 307 (2.8) 145 (20.6) 1712 (16.9) 0.014 100 (20.4) 107 (21.8) 0.639 −6.4
Amiodarone 661 (6.1) 310 (2.8) 56 (7.9) 605 (6) 0.042 35 (7.1) 40 (8.2) 0.631 −13.4
Digoxin 1637 (15.1) 313 (2.8) 72 (10.2) 1565 (15.4) < 0.001 52 (10.6) 49 (10.0) 0.834 +6.0
Vitals at ED during acute episode
SBP (mmHg) (mean (SD)) 141 (27) 172 (1.5) 149 (34) 141 (27) < 0.001 149 (32) 149 (32) 0.764 0
Heart rate (bpm) (mean (SD)) 88.2 (23.7) 240 (2.2) 97.1 (25.8) 87.6 (23.5) < 0.001 95 (25) 95 (25) 0.866 0
Air-room pulse oximetry (%)
(mean (SD))
92.2 (6.5) 350 (3.1) 87.8 (9.7) 92.6 (6.1) < 0.001 88 (8) 88 (10) 0.736 0
Analytical data at ED
Glycemia (mg/dL) (median (SD)) 146 (82) 184 (1.6) 184 (95) 143 (80) < 0.001 173 (78) 176 (104) 0.589 −1.7
Creatinine (mg/dL) (median
(SD))
1.35 (0.92) 128 (1.1) 1.56 (1.05) 1.33 (0.90) < 0.001 1.56 (1.08) 1.46 (1.04) 0.155 +6.8
Hemoglobin (g/L) (median (SD)) 121 (43) 96 (9) 120 (27) 121 (44) 0.755 121 (29) 123 (68) 0.475 −1.6
Potassium (mmol/L) (median
(SD))
4.6 (5.4) 684 (6.1) 4.9 (5.5) 4.6 (5.4) 0.124 4.9 (6.4) 4.5 (2.1) 0.160 +8.9
Sodium (mmol/L) (median (SD)) 137 (13) 185 (1.7) 137 (7) 137 (13) 0.457 137 (8.1) 139 (45.6) 0.359 −1.4
Troponin positive 3578 (57.6) 4935 (44.3) 297 (60.5) 3281 (57.3) 0.185 189 (57.4) 171 (60.0) 0.577 −4.3
Management at ED
Receiving any intravenous
diuretic
9440 (84.7) 3 (0.0) 660 (91.9) 8780 (84.2) < 0.001 460 (93.9) 460 (93.9) 1.000 0
Receiving intravenous nitrates 1517 (13.6) 1 (0.0) 351 (48.9) 1166 (11.2) < 0.001 218 (44.5) 217 (44.3) 1.000 +0.5
Receiving intravenous morphine 682 (6.1) 1 (0.) 267 (37.2) 415 (4) < 0.001 143 (29.2) 147 (30.0) 0.834 −2.7
Receiving inotropics/
vasopressors
194 (1.7) 6 (0.1) 44 (6.1) 150 (1.4) < 0.001 25 (5.1) 23 (4.7) 0.882 +8.5
Admission at hospital 8439 (75.7) 6 (0.1) 690 (96.1) 7749 (74.3) < 0.001 476 (97.1) 472 (96.3) 0.590 +0.8
NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; ACE: angiotensin-converting enzyme; ARB: angiotensin-II receptor blocker; SBP: systolic blood pressure; ED:
emergency department.
a RD denotes relative difference between mean of proportion of the NIV+ group respect to the NIV- group.
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hypotensive patients as it can decrease SBP, and they recognize that
data on mortality are currently inconclusive [12]. Finally, the American
College of Cardiology Foundation/American Heart Association guide-
lines do not make any specific statement regarding NIV use during an
AHF decompensation [19]. In this scenario of conflicting guidelines,
emergency physicians use NIV based on their own experience, clinical
skills and subjective feelings rather than in well-defined patient pro-
files, likely leading to some heterogeneity in NIV use among ED phy-
sicians, and thereby influencing, in part, the results obtained in the NIV-
AHF Study.
The second potential explanation of our findings is the possibility
that NIV has become a ceiling therapy for some of severely ill patients.
This concept could likely explain the non-statistically significant trends
homogenously pointing towards worse results with NIV use in our co-
hort, in which the mean patient age was 80 years and with many
patients presenting some functional limitations. In this scenario, the
failure of NIV may not necessarily be followed by ETI and mechanical
ventilation as some terminal patients could represent a cohort re-
cognized as being in a “last hours situation”. Unfortunately, we did not
identify palliative care patients in our cohort. If supportive care patients
with poor and extremely bad prognosis were included in the NIV+
group, PS matching would not balance for this, thereby confounding
our results.
Although these two facts may provide arguments against the re-
levance of our findings, we feel that it is of note that the mortality did
not increase with NIV in the majority of our patients (not very eldery,
had hypotension or had concomitant ACS). In addition, it should also be
highlighted that the type of NIV was not related to outcomes. This is
consistent with physiologic understanding of how these different stra-
tegies function. The clinical utility of a temporizing strategy allowing
NIV- Group
Patients on risk 10,434 10,138 9,933 9,783 9,654 9,519 9,312
Events 0 280 479 623 739 845 928
NIV+ Group
Patients on risk 718 656 630 610 594 585 569
Events 0 62 88 106 120 129 135
Log-rank test p<0.001
HR for NIV+ Group = 2.229 (95%CI=1.861-2.610)
NIV+ Group (n=718)
NIV- Group (controls. n=10,434)
NIV- Group
Patients on risk 10,434 10,138 9,933 9,783 9,654 9,519 9,312
Events 0 280 479 623 739 845 928
CPAP Group
Patients on risk 317 282 273 266 259 255 249
Events 0 35 44 50 57 61 64
BiPAP Group
Patients on risk 380 354 337 324 316 311 301
Events 0 26 43 55 61 66 69
Log-rank test p<0.001
HR for NIV+ Group; CPAP mode = 2.437 (95%CI=1.892-3.139)
HR for NIV+ Group; BiPAP mode = 2.130 (95%CI=1.668-2.719)
NIV+ Group; CPAP mode (n=317)
NIV- Group (controls. n=10,434)
NIV+ Group; BiPAP mode (n=380)
Fig. 2. Kaplan-Meier survival curves for the whole cohort of patients treated with non-invasive ventilation (NIV) with respect to those who did not receive NIV (left), and subgroup
analysis depending on the type of NIV used in the emergency department (CPAP: continuous positive airway pressure; BiPAP: bilevel positive airway pressure). Unadjusted (left) and
adjusted (right) proportional risk for patients that were treated with non-invasive ventilation (NIV) with respect to those who did not receive NIV.
NIV+ Group (n=490)
NIV- Group (controls. n=490)
Log-rank test p=0.182
HR for NIV+ Group = 1.239 (95%CI=0.905-1.696)
NIV- Group
Paents on risk 490 465 449 436 427 421 409
Events 0 25 41 53 59 65 70
NIV+ Group
Paents on risk 490 456 436 422 409 403 391
Events 0 34 54 66 77 83 86
NIV+ Group; CPAP mode (n=196)
NIV- Group (controls. n=490)
NIV+ Group; BiPAP mode (n=280)
Log-rank test p=0.386
HR for NIV+ Group; CPAP mode = 1.263 (95%CI=0.842-1.893)
HR for NIV* Group; BiPAP mode = 1.235 (95%CI=0.858-1.778)
NIV- Group
Paents on risk 490 465 449 436 427 421 409
Events 0 25 41 53 59 65 70
CPAP Group
Paents on risk 196 182 174 170 164 161 157
Events 0 14 22 25 31 34 35
BiPAP Group
Paents on risk 280 261 249 239 233 230 222
Events 0 19 31 40 44 47 49
Fig. 3. Kaplan-Meier survival curves for propensity score-matched patients treated with non-invasive ventilation (NIV) compared to those who did not receive NIV (left), and subgroup
analysis depending on the type of NIV used in the emergency department (CPAP: continuous positive airway pressure; BiPAP: bilevel positive airway pressure).
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alternative interventions (e.g., pharmacologic treatments) to poten-
tially impart a beneficial effect before the patient required ETI and
invasive ventilation did not change regardless of whether CPAP or
BIPAP were used. It is important to recognize that NIV is not a desti-
nation therapy. It is used in an effort to avoid more invasive interven-
tions that address severe respiratory compromise (e.g., ETI). As such,
avoidance of ETI is an important outcome as patients receiving me-
chanical ventilation markedly increase resource utilization and are also
at a much greater risk of aspiration and hospital-acquired pneumonia as
compared to a non-intubated cohort [20,21].
Special circumstances in which NIV use could imply increased risk
merit discussion. There is general agreement that failure to improve the
prognosis of patients with AHF during the last decades has been due, in
part, to the lack of a definition of the different scenarios and different
therapeutic approaches, as well as the unclear transition strategies
undertaken in a paradigmatic multidisciplinary syndrome such as AHF
[22–24]. Therefore, the targets of therapy for AHF should not only be to
improve symptoms and hemodynamics, but also to preserve or improve
renal function, prevent myocardial damage, modulate neurohumoral
and inflammatory activation, manage other comorbidities, identify
precipitants, and avoid secondary effects of treatments in particular
subgroups of patients [24–26]. In the present study we identified that in
patients with an ACS (different from STEMI, as this was an exclusion
criteria), low SBP (< 100mmHg) and advanced age (> 85 years) NIV
should probably be avoided. With respect to ACS, although mortality in
those patients requiring NIV is increased respect the those not needing
ventilatory support and decreased respect to those needing mechanical
ventilation [27,28], there are no RCT analyzing if the net effect of NIV
in patients with ACS. On the other hand, although advanced age is
associated with the use of NIV as limitation therapy, there is no clear
cut-off for age in this sense. It seems reasonable that when applied to
most elderly patients, NIV could be associated with worse outcomes due
to its use as limitation therapy or related to the advanced age per se.
However, regarding the latter, some recent data suggest that NIV suc-
cess and mortality rates were similar between age groups [29]. Finally,
with regard to hypotension, a recent study suggested that NIV could be
effective in selected patients with cardiogenic shock, although when
ventilatory support is needed, mechanical ventilation is the preferred
option for most of these patients [30]. Again, in the absence of selection
criteria for AHF patients with low SBP, our data agree with the ESC
guidelines recommendations [12] of avoiding NIV use in the ED arena
in hypotensive patients.
Our study has limitations. As an observational study, it is difficult to
determine causality. The patients were not randomized and physicians
could tend to reserve NIV for more severely ill cohorts. Propensity score
matching attempted to adjust for known and measurable factors, but
could not control for undocumented, unrecorded, or unknown variables
and as such their consequences cannot be commented upon. Second,
the impact of physician prescribing cannot be determined. It cannot be
determined whether NIV+ patients received the same therapeutic al-
gorithmic care as NIV- patients because the individual time and drug
used (e.g., mg/h of nitroglycerin) were not recorded. It is possible that
the presence of NIV masks decreased the frequency of sublingual ni-
troglycerin dosing, and that other factors resulted in therapeutic dif-
ferences between NIV+ and NIV- patients, possibly altering outcomes.
The extent of this impact is unknown and was not measured. Third, we
did not record whether the NIV was started by EMS in some patients,
the delay in starting NIV after patient arrival to ED, or the total time
0.010.11.0
Age
d85 years
>85 years
Sex
Female
Male
Previous ischemic cardiomyopathy
Not
Yes
Chronic obstructive pulmonary disease
Not
Yes
AHF associated with ACS
Not
Yes
Hypertensive AHF / Acute pulmonary edema
Not
Yes
Systolic blood pressure
e100 mmHg
<100 mmHg
Hazard ratio for 30-day mortality (95% CI)
For patients receiving NIV at emergency department
P for
interacon
Hazard
rao
Lower
limit
Upper
limit p
<0.001
1.132 0.721 1.777 0.591
1.454 0.938 2.253 0.094
0.064
1.662 1.088 2.539 0.019
0.844 0.522 1.365 0.490
0.203
1.264 0.876 1.823 0.210
1.120 0.594 2.056 0.751
0.437
1.516 1.024 2.246 0.036
0.847 0.496 1.446 0.543
<0.045
1.193 0.864 1.649 0.284
2.323 0.468 11.528 0.302
0.063
1.141 0.795 1.639 0.474
1.494 0.785 2.846 0.221
<0.001
1.197 0.862 1.661 0.282
2.133 0.696 6.538 0.185
Fig. 4. Stratified analysis and evaluation of interaction for the primary endpoint of 30-day mortality in patients treated with non-invasive ventilation (NIV) at the emergency department.
AHF: acute heart failure; ACS: acute coronary syndrome.
Table 2
Analysis of secondary endpoints in the two groups of patients matched by the propensity
score.
NIV+
group
NIV-
group
OR (95% CI) for NIV
+ group
P value
(n (%)) (n (%))
ICU admission 29 (5.9) 17 (3.5) 1.754 (0.951–3.236) 0.072
Mechanical ventilation 9 (1.8) 11 (2.2) 0.815 (0.335–1.984) 0.652
3-day mortality 29 (5.9) 22 (4.5) 1.338 (0.758–2.364) 0.316
7-day mortality 47 (9.6) 36 (7.3) 1.338 (0.850–2.106) 0.208
In-hospital mortality 81 (16.5) 61
(12.4)
1.393 (0.973–1.994) 0.070
Prolonged length of
stay (> 7 days)
261
(53.9)
217
(44.7)
1.445 (1.122–1.862) 0.004
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that patients remained on NIV. Therefore, a particular subgroup of
patients such as those with premature NIV weaning could have had a
worse prognosis and possibly leaned the NIV+ group towards a trend
to worse results. Fourth, and similar to the latter limitation, aside from
the mode (CPAP/BIPAP) of use ventilator parameters were not re-
corded, and in this scenario, it is again possible that ventilator condi-
tions might not have been the most adequate in a subgroup of patients.
Lastly, the NIV-AHF study only evaluated the effect of NIV use in the
ED, and it is possible that in some of our patients NIV could have been
applied after they had been hospitalized.
We can conclude that NIV does not increase mortality in AHF except
in the very eldery population (> 85 years), hypotensive patients
(SBP<100mmHg), or in patients with AHF associated with ACS. It
should generally not be used in these conditions. However, NIV may be
appropriate in AHF when used to provide short-term symptom relief, or
as a bridge to avoid ETI. Finally, since NIV does not ultimately have an
impact on mortality, it should not be considered as definitive therapy
but rather as a temporizing intervention.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ejim.2018.03.008.
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